Infliximab is effective in corticosteroid-refractory ulcerative colitis
As reported in the Journal of Crohn’s & Colitis, treatment of corticosteroid-refractory ulcerative colitis patients with 3 doses of infliximab (n=113) resulted in short- (3 months) and long-term (12 months) colectomy rates of 18.6% and 25.6%, respectively. The RR of colectomy in patients with an elevated CRP and severe endoscopic lesions was 2.15 and 5.13, respectively.
SIRT3 expression improves prognosis in gastric cancer
As reported in the World Journal of Surgery, SIRT3 expression improves the prognosis in patients with gastric cancer (n=221). Specifically, the 5-year OS was 51.2% and 39.1% in patients who do and do not express SIRT3, respectively. The 5-year DFS was 49.6% and 38.0% in patients who do and do not express SIRT3, respectively. Patients who do not express SIRT3 are characterized by increased poor cellular differentiation, increased diffuse-type Lauren’s histology, and increases scirrhous-type stromal reactions, suggesting the SIRT3 functions as a tumor suppressor.
Decreased PTPN12 expression associated with poor prognosis in HCC
As reported in PLoS ONE, the expression of PTPN12 was decreased in hepatocellular carcinoma tissue samples compared with adjacent normal tissues. Furthermore, decreased PTPN12 expression was associated with tumor recurrence, decreased cancer-specific survival, and decreased recurrence-free survival.